NASDAQ:AXGN - AxoGen Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $23.50
  • Forecasted Upside: 156.83 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$9.15
▲ +0.04 (0.44%)

This chart shows the closing price for AXGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AxoGen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AXGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AXGN

Analyst Price Target is $23.50
▲ +156.83% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for AxoGen in the last 3 months. The average price target is $23.50, with a high forecast of $27.00 and a low forecast of $20.00. The average price target represents a 156.83% upside from the last price of $9.15.

This chart shows the closing price for AXGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in AxoGen. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/19/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/18/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/17/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/4/2021JMP SecuritiesReiterated RatingBuy$25.00 ➝ $20.00High
10/22/2021SVB LeerinkReiterated RatingOutperformHigh
5/31/2021SVB LeerinkReiterated RatingBuy$27.00Medium
2/23/2021SVB LeerinkBoost Price TargetOutperform$23.00 ➝ $27.00Medium
1/12/2021Cantor FitzgeraldBoost Price TargetOverweight$16.00 ➝ $23.00High
10/22/2020GuggenheimInitiated CoverageBuy$24.00Low
8/6/2020SVB LeerinkBoost Price TargetOutperform$13.50 ➝ $15.50High
8/5/2020BTIG ResearchReiterated RatingHoldHigh
7/1/2020BTIG ResearchDowngradeHoldHigh
6/15/2020Cantor FitzgeraldInitiated CoverageBuy$16.00Low
6/8/2020Cantor FitzgeraldReiterated RatingOverweightLow
4/2/2020BTIG ResearchDowngradeBuy ➝ NeutralHigh
12/16/2019BTIG ResearchReiterated RatingBuy$21.00High
8/7/2019JMP SecuritiesLower Price TargetOutperform$43.00 ➝ $28.00Medium
8/7/2019BTIG ResearchLower Price TargetBuy$21.00High
8/7/2019William BlairDowngradeOutperform ➝ Market PerformHigh
8/7/2019Cantor FitzgeraldLower Price TargetOverweight$30.00 ➝ $21.00High
5/10/2019BTIG ResearchReiterated RatingBuy$29.00Medium
5/9/2019Cantor FitzgeraldReiterated RatingOverweight$26.00 ➝ $30.00High
4/22/2019Cantor FitzgeraldSet Price TargetBuy$26.00Low
3/25/2019BTIG ResearchUpgradeNeutral ➝ Buy$28.00High
1/18/2019Cantor FitzgeraldSet Price TargetBuy$26.00Low
12/19/2018Cantor FitzgeraldReiterated RatingBuy$43.00High
11/14/2018BTIG ResearchInitiated CoverageNeutralHigh
10/30/2018Cantor FitzgeraldLower Price TargetOverweight ➝ Overweight$45.00 ➝ $43.00Medium
10/30/2018SVB LeerinkReiterated RatingOutperform$55.00High
8/9/2018Cantor FitzgeraldReiterated RatingBuy$45.00Low
6/26/2018SVB LeerinkReiterated RatingOutperform$70.00High
5/1/2018JMP SecuritiesBoost Price TargetMarket Outperform ➝ Market Outperform$34.00 ➝ $43.00High
5/1/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$37.00 ➝ $45.00High
3/19/2018Jefferies Financial GroupBoost Price TargetBuy$45.00Medium
3/2/2018Lake Street CapitalSet Price TargetBuy ➝ Buy$26.00 ➝ $38.00Medium
3/1/2018JMP SecuritiesBoost Price TargetMarket Outperform$27.00 ➝ $34.00High
2/5/2018William BlairInitiated CoverageOutperformHigh
1/8/2018Cantor FitzgeraldSet Price TargetBuy$37.00High
1/5/2018Cantor FitzgeraldReiterated RatingOverweight ➝ OverweightHigh
11/30/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$35.00High
11/21/2017SVB LeerinkBoost Price TargetOutperform ➝ Outperform$26.00 ➝ $30.00N/A
11/21/2017Lake Street CapitalBoost Price TargetBuy ➝ Buy$22.00 ➝ $26.00N/A
11/21/2017WedbushReiterated RatingBuy$22.00 ➝ $27.00N/A
11/2/2017SVB LeerinkBoost Price TargetOutperform$23.00 ➝ $26.00N/A
9/30/2017SVB LeerinkReiterated RatingOutperform$22.00 ➝ $23.00Medium
9/12/2017Roth CapitalReiterated RatingBuy$18.00 ➝ $21.00Low
8/21/2017Cantor FitzgeraldReiterated RatingBuy$18.00Low
7/31/2017SVB LeerinkInitiated CoverageOutperform ➝ Outperform$22.00High
6/29/2017Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$18.00High
5/19/2017WedbushReiterated RatingOutperform$17.00 ➝ $14.00High
3/6/2017Roth CapitalInitiated CoverageBuy ➝ Buy$14.50N/A
(Data available from 1/17/2017 forward)

News Sentiment Rating

0.66 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/21/2021
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/20/2021
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/19/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
10/19/2021
  • 2 very positive mentions
  • 4 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
11/18/2021
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/18/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/17/2022

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
AxoGen logo
Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm's products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.
Read More

Today's Range

Now: $9.15
Low: $8.87
High: $9.29

50 Day Range

MA: $10.04
Low: $8.80
High: $13.40

52 Week Range

Now: $9.15
Low: $8.48
High: $23.94

Volume

276,909 shs

Average Volume

543,690 shs

Market Capitalization

$380.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.78

Frequently Asked Questions

What sell-side analysts currently cover shares of AxoGen?

The following Wall Street research analysts have issued reports on AxoGen in the last twelve months: JMP Securities, and SVB Leerink LLC.
View the latest analyst ratings for AXGN.

What is the current price target for AxoGen?

2 Wall Street analysts have set twelve-month price targets for AxoGen in the last year. Their average twelve-month price target is $23.50, suggesting a possible upside of 156.8%. SVB Leerink LLC has the highest price target set, predicting AXGN will reach $27.00 in the next twelve months. JMP Securities has the lowest price target set, forecasting a price of $20.00 for AxoGen in the next year.
View the latest price targets for AXGN.

What is the current consensus analyst rating for AxoGen?

AxoGen currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AXGN will outperform the market and that investors should add to their positions of AxoGen.
View the latest ratings for AXGN.

What other companies compete with AxoGen?

How do I contact AxoGen's investor relations team?

AxoGen's physical mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider's listed phone number is (386) 462-6800 and its investor relations email address is [email protected] The official website for AxoGen is www.axogeninc.com.